Now showing items 1-1 of 1

    • Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial 

      Munro, A. P. S.; Janani, L.; Cornelius, V.; Aley, P. K.; Babbage, G.; Baxter, D.; Bula, M.; Cathie, K.; Chatterjee, K.; Dodd, K.; Enever, Y.; Gokani, K.; Goodman, A. L.; Green, C. A.; Harndahl, L.; Haughney, J.; Hicks, A.; van der Klaauw, A. A.; Kwok, J.; Lambe, T.; Libri, V.; Llewelyn, M. J.; McGregor, A. C.; Minassian, A. M.; Moore, P.; Mughal, M.; Mujadidi, Y. F.; Murira, J.; Osanlou, O.; Osanlou, R.; Owens, D. R.; Pacurar, M.; Palfreeman, A.; Pan, D.; Rampling, T.; Regan, K.; Saich, S.; Salkeld, J.; Saralaya, D.; Sharma, S.; Sheridan, R.; Sturdy, A.; Thomson, E. C.; Todd, S.; Twelves, C.; Read, R. C.; Charlton, S.; Hallis, B.; Ramsay, M.; Andrews, N.; Nguyen-Van-Tam, J. S.; Snape, M. D.; Liu, X.; Faust, S. N. (Elsevier, 2021-12-18)
      BACKGROUND: Few data exist on the comparative safety and immunogenicity of different COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of booster vaccines, we investigated the ...